Related Experiment Videos
Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma
1Department of Urology, University of Washington, Seattle, USA.
Cancer
|July 15, 1996
Summary
Quantifying microvessel density (MVD) in prostate cancer offers a more accurate prediction of disease stage and patient outcomes than traditional methods. This technique, applicable to core needle biopsies, aids in treatment decisions and monitoring.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Accurate prediction of prostate cancer's pathologic stage and malignant potential is currently limited.
- Improved methods are crucial for effective therapy recommendations and prognostic assessments.
- Microvessel density (MVD) quantification shows promise in predicting tumor aggressiveness across various organ systems.
Purpose of the Study:
- To evaluate the utility of quantitative microvessel density (MVD) in assessing pathologic stage and predicting progression in prostate cancer patients.
- To determine if MVD quantification provides superior predictive information compared to existing clinical markers.
Main Methods:
- Investigating quantitative microvessel density (MVD) as a preoperative assessment tool for prostate cancer.
- Analyzing MVD in limited tissue samples obtained via prostate core needle biopsy.
Main Results:
- Quantitative MVD provides unique and valuable staging information for prostate cancer.
- MVD quantification is a superior predictor of radical prostatectomy findings compared to clinical stage, PSA, and Gleason score.
- MVD analysis, applied across various therapeutic modalities, offers additional predictive power for patient progression.
Conclusions:
- Quantitative MVD offers significant staging and prognostic insights for prostate cancer.
- MVD results can guide decisions on further staging, patient stratification for therapy, and monitoring strategies.
- This method may influence the technical aspects of definitive treatment planning.